COMPOSITIONS AND METHODS FOR INCREASING THE METABOLIC LIFETIME OF DEXTROMETHORPHAN AND RELATED PHARMACODYNAMIC EFFECTS
First Claim
1. A method of increasing dextromethorphan plasma levels in a human being, comprising co-administering between about 50 mg per day and about 250 mg per day of bupropion with dextromethorphan to the human being for at least eight consecutive days, wherein the human being is an extensive metabolizer of dextromethorphan and in need of treatment with dextromethorphan, wherein the dextromethorphan plasma level on the first day bupropion is co-administered with dextromethorphan is at least about 10 times the level that would be achieved by administering the same amount of dextromethorphan without bupropion, and wherein the co-administration results in an AUC0-12 of dextromethorphan that on the eighth day, is at least about 20 times the AUC0-12 that would be achieved by administering the same amount of dextromethorphan without bupropion for eight consecutive days.
3 Assignments
0 Petitions
Accused Products
Abstract
Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.
103 Citations
30 Claims
- 1. A method of increasing dextromethorphan plasma levels in a human being, comprising co-administering between about 50 mg per day and about 250 mg per day of bupropion with dextromethorphan to the human being for at least eight consecutive days, wherein the human being is an extensive metabolizer of dextromethorphan and in need of treatment with dextromethorphan, wherein the dextromethorphan plasma level on the first day bupropion is co-administered with dextromethorphan is at least about 10 times the level that would be achieved by administering the same amount of dextromethorphan without bupropion, and wherein the co-administration results in an AUC0-12 of dextromethorphan that on the eighth day, is at least about 20 times the AUC0-12 that would be achieved by administering the same amount of dextromethorphan without bupropion for eight consecutive days.
- 20. A method, comprising co-administering between about 30 mg per day and about 120 mg per day of dextromethorphan with bupropion to a human being in need of treatment with dextromethorphan, wherein dextromethorphan and bupropion are co-administered to the human being once or twice a day for at least eight consecutive days, wherein the co-administration is effective for converting the human being from an extensive metabolizer of dextromethorphan to a lesser metabolizer of dextromethorphan, and wherein the co-administration results in an AUC0-12 of dextromethorphan that on the eighth day, is at least about 20 times the AUC0-12 that would be achieved by administering the same amount of dextromethorphan without bupropion for eight consecutive days.
Specification